Private Advisor Group LLC Has $59.35 Million Position in Eli Lilly and Company (NYSE:LLY)

Private Advisor Group LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 0.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 76,282 shares of the company’s stock after purchasing an additional 430 shares during the quarter. Private Advisor Group LLC’s holdings in Eli Lilly and Company were worth $59,345,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Norges Bank acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at $5,992,890,000. International Assets Investment Management LLC lifted its stake in Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after buying an additional 7,330,815 shares during the period. Sapient Capital LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $682,139,000. Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after buying an additional 659,838 shares during the period. Finally, Comerica Bank acquired a new position in Eli Lilly and Company in the third quarter valued at about $345,781,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 92,563 shares of the stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the transaction, the insider now directly owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the sale, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 92,563 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $809.21, for a total value of $74,902,905.23. Following the completion of the sale, the insider now directly owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 858,742 shares of company stock valued at $735,573,781. Insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of several analyst reports. BMO Capital Markets reissued an “outperform” rating and issued a $1,001.00 target price on shares of Eli Lilly and Company in a research note on Wednesday. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Citigroup increased their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Jefferies Financial Group increased their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Finally, Morgan Stanley restated an “overweight” rating and issued a $1,023.00 price target on shares of Eli Lilly and Company in a report on Friday. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $816.78.

Eli Lilly and Company Stock Up 1.8 %

NYSE LLY traded up $16.47 during trading hours on Friday, hitting $914.57. 2,880,863 shares of the company traded hands, compared to its average volume of 2,607,195. The business’s 50-day moving average is $831.69 and its 200-day moving average is $750.06. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $918.50. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The stock has a market capitalization of $869.22 billion, a price-to-earnings ratio of 134.69, a P/E/G ratio of 1.96 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the prior year, the firm posted $1.62 earnings per share. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. Sell-side analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.57%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.